Emergent BioSolutions Inc. (EBS)
NYSE: EBS · Real-Time Price · USD
9.12
-0.06 (-0.65%)
May 29, 2026, 4:00 PM EDT - Market closed
Emergent BioSolutions Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 676.8 | 742.9 | 1,044 | 1,049 | 1,118 | 1,774 | |
Revenue Growth (YoY) | -29.89% | -28.81% | -0.54% | -6.10% | -36.99% | 12.45% |
Cost of Revenue | 309.7 | 326.2 | 681.3 | 705.4 | 693.1 | 748.1 |
Gross Profit | 367.1 | 416.7 | 362.3 | 343.9 | 424.4 | 1,026 |
Selling, General & Admin | 180.3 | 186.1 | 308 | 368.4 | 339.5 | 348.7 |
Depreciation & Amortization Expenses | 65.3 | 65.1 | 65.1 | 65.6 | 59.9 | 58.5 |
Research & Development | 48.6 | 53.2 | 70.7 | 111.4 | 188.3 | 235.2 |
Other Operating Expenses | 12.2 | 12.2 | 27.2 | 524.9 | 6.7 | 41.7 |
Total Operating Expenses | 306.4 | 316.6 | 471 | 1,070 | 594.4 | 684.1 |
Operating Income | 60.7 | 100.1 | -108.7 | -726.4 | -170 | 341.4 |
Interest Expense | -55.6 | -59.3 | -71 | -87.9 | -37.3 | -34.5 |
Other Non-Operating Income (Expense) | 25 | 66.4 | 36.8 | 83.1 | -11.7 | -3.7 |
Total Non-Operating Income (Expense) | -30.6 | 7.1 | -34.2 | -4.8 | -49 | -38.2 |
Pretax Income | 3.5 | 82.8 | -142.9 | -731.2 | -219 | 303.2 |
Provision for Income Taxes | 5.7 | 30.2 | 47.7 | 29.3 | -7.4 | 83.7 |
Net Income | -8.6 | 52.6 | -190.6 | -760.5 | -211.6 | 219.5 |
Net Income to Common | -8.6 | 52.6 | -190.6 | -760.5 | -211.6 | 219.5 |
Net Income Growth | - | - | - | - | - | -28.22% |
Shares Outstanding (Basic) | 53 | 54 | 53 | 51 | 50 | 54 |
Shares Outstanding (Diluted) | 55 | 57 | 53 | 51 | 50 | 54 |
Shares Change (YoY) | -0.05% | 6.98% | 3.52% | 2.20% | -7.39% | 0.56% |
EPS (Basic) | -0.17 | 0.98 | -3.60 | -14.85 | -4.22 | 4.10 |
EPS (Diluted) | -0.28 | 0.93 | -3.60 | -14.85 | -4.22 | 4.06 |
EPS Growth | - | - | - | - | - | -28.52% |
Shares Outstanding | 51.8 | 52.1 | 54.18 | 52.2 | 50.1 | 51.3 |
Free Cash Flow | 135.4 | 156.8 | 35.8 | -257.9 | -149.9 | 96.1 |
Free Cash Flow Growth | -13.65% | 337.99% | - | - | - | -75.67% |
Free Cash Flow Per Share | 2.47 | 2.77 | 0.68 | -5.04 | -2.99 | 1.78 |
Gross Margin | 54.24% | 56.09% | 34.72% | 32.77% | 37.98% | 57.82% |
Operating Margin | 8.97% | 13.47% | -10.42% | -69.23% | -15.21% | 19.25% |
Profit Margin | -1.27% | 7.08% | -18.26% | -72.48% | -18.94% | 12.38% |
FCF Margin | 20.01% | 21.11% | 3.43% | -24.58% | -13.41% | 5.42% |
EBITDA | 163.9 | 205.7 | 7.5 | -580 | -22.6 | 469.3 |
EBITDA Margin | 24.22% | 27.69% | 0.72% | -55.27% | -2.02% | 26.46% |
EBIT | 60.7 | 100.1 | -108.7 | -726.4 | -170 | 341.4 |
EBIT Margin | 8.97% | 13.47% | -10.42% | -69.23% | -15.21% | 19.25% |
Effective Tax Rate | 162.86% | 36.47% | -33.38% | -4.01% | 3.38% | 27.61% |